Equity (Details) - Schedule of fair value of the options using the Black-Scholes option-pricing model |
6 Months Ended |
---|---|
Jun. 30, 2021
$ / shares
shares
| |
Number of Options | |
Equity (Details) - Schedule of fair value of the options using the Black-Scholes option-pricing model [Line Items] | |
Nonvested at beginning balance | shares | 218,334 |
Number of Options Granted | shares | 640,000 |
Number of Options Vested | shares | (438,334) |
Nonvested at ending balance | shares | 420,000 |
Weighted Average Exercise Price | |
Equity (Details) - Schedule of fair value of the options using the Black-Scholes option-pricing model [Line Items] | |
Nonvested at beginning balance | $ / shares | $ 1.18 |
Weighted Average Exercise Price Granted | $ / shares | 1.10 |
Weighted Average Exercise Price Vested | $ / shares | (1.15) |
Nonvested at ending balance | $ / shares | $ 1.08 |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of non-vested options outstanding. No definition available.
|
X | ||||||||||
- Definition Weighted average grant-date fair value of non-vested options outstanding. No definition available.
|
X | ||||||||||
- Definition Weighted average grant-date fair value of options vested. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|